Pharmigene, Inc. (TPEX:7595)

Pharmigene Statistics

Total Valuation

Pharmigene has a market cap or net worth of TWD 623.24 million. The enterprise value is 1.17 billion.

Market Cap	623.24M
Enterprise Value	1.17B

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Pharmigene has 50.47 million shares outstanding. The number of shares has increased by 3.03% in one year.

Current Share Class	50.47M
Shares Outstanding	50.47M
Shares Change (YoY)	+3.03%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	7.62%
Owned by Institutions (%)	n/a
Float	32.12M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.18
PB Ratio	2.01
P/TBV Ratio	2.11
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-15.43
EV / Sales	7.81
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-13.79

Financial Position

The company has a current ratio of 2.46, with a Debt / Equity ratio of 1.99.

Current Ratio	2.46
Quick Ratio	1.62
Debt / Equity	1.99
Debt / EBITDA	n/a
Debt / FCF	-7.30
Interest Coverage	-5.10

Financial Efficiency

Return on equity (ROE) is -21.55% and return on invested capital (ROIC) is -4.40%.

Return on Equity (ROE)	-21.55%
Return on Assets (ROA)	-4.25%
Return on Invested Capital (ROIC)	-4.40%
Return on Capital Employed (ROCE)	-7.58%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	42
Asset Turnover	0.15
Inventory Turnover	2.47

Taxes

In the past 12 months, Pharmigene has paid 25,000 in taxes.

Income Tax	25,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.77% in the last 52 weeks. The beta is 0.11, so Pharmigene's price volatility has been lower than the market average.

Beta (5Y)	0.11
52-Week Price Change	-23.77%
50-Day Moving Average	11.68
200-Day Moving Average	12.55
Relative Strength Index (RSI)	54.02
Average Volume (20 Days)	60,848

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharmigene had revenue of TWD 149.25 million and -75.51 million in losses. Loss per share was -1.50.

Revenue	149.25M
Gross Profit	47.89M
Operating Income	-67.60M
Pretax Income	-75.48M
Net Income	-75.51M
EBITDA	-46.20M
EBIT	-67.60M
Loss Per Share	-1.50

Balance Sheet

The company has 75.20 million in cash and 616.97 million in debt, giving a net cash position of -541.77 million or -10.74 per share.

Cash & Cash Equivalents	75.20M
Total Debt	616.97M
Net Cash	-541.77M
Net Cash Per Share	-10.74
Equity (Book Value)	310.33M
Book Value Per Share	6.15
Working Capital	105.62M

Cash Flow

In the last 12 months, operating cash flow was -45.14 million and capital expenditures -39.36 million, giving a free cash flow of -84.50 million.

Operating Cash Flow	-45.14M
Capital Expenditures	-39.36M
Free Cash Flow	-84.50M
FCF Per Share	-1.67

Margins

Gross margin is 32.09%, with operating and profit margins of -45.29% and -50.59%.

Gross Margin	32.09%
Operating Margin	-45.29%
Pretax Margin	-50.57%
Profit Margin	-50.59%
EBITDA Margin	-30.96%
EBIT Margin	-45.29%
FCF Margin	n/a

Dividends & Yields

Pharmigene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.03%
Shareholder Yield	n/a
Earnings Yield	-12.12%
FCF Yield	-13.56%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Pharmigene has an Altman Z-Score of 0.44 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.44
Piotroski F-Score	3